IgG4 antibody | HP6023
Mouse anti Human IgG4 antibody, clone HP6023 recognises the pFc' region of human IgG4.
- Target Species
- Product Form
- Purified IgG - liquid
- Purified IgG prepared from tissue culture supernatant
- Buffer Solution
- Borate buffered saline
- Preservative Stabilisers
- None present
- Pool of 5-6 individually purified Human IgG4 myeloma proteins
- Approx. Protein Concentrations
- IgG concentration 0.5 mg/ml
- Store at -20oC only.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- Guaranteed until date of expiry. Please see product label.
- P01861 Related reagents
- Entrez Gene
- IGHG4 Related reagents
- GO Terms
- GO:0003823 antigen binding
- GO:0005576 extracellular region
- GO:0005624 membrane fraction
- GO:0006955 immune response
- For research purposes only
Applications of IgG4 antibody
|Application Name||Verified||Min Dilution||Max Dilution|
|Immunohistology - Frozen|
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Copyright © 2019 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Product Specific References
References for IgG4 antibody
Mutapi, F. et al. (2002) The effect of treatment on the age-antibody relationship in children infected with Schistosoma mansoni and Schistosoma haematobium.
Mem Inst Oswaldo Cruz. 97 Suppl 1: 173-80.
Martinsson, K. et al. (2017) Immunoglobulin (Ig)G1 and IgG4 anti-cyclic citrullinated peptide (CCP) associate with shared epitope, whereas IgG2 anti-CCP associates with smoking in patients with recent-onset rheumatoid arthritis (the Swedish TIRA project).
Clin Exp Immunol. 188 (1): 53-62.